



## **Living Cell Technologies Limited**

**ACN:** 104 028 042

**ASX:** LCT

**OTCQB:** LVCLY

### **ASX ANNOUNCEMENT**

## Choroid plexus tissue shipped to Sydney as NTCELL research advances

---

### **Highlights**

- **Choroid plexus tissue successfully shipped to Sydney from NZeno's Invercargill facility following import approval**
- **LCT commencing preparations for manufacturing of NTCELL, in preparation for third clinical trial of NTCELL in Parkinson's disease.**

**Sydney, Australia & Auckland, New Zealand – 16 August 2022** – Living Cell Technologies (ASX:LCT; OTCQB:LVCLY) has advanced its Parkinson's disease research, with choroid plexus tissue successfully shipped from New Zealand to Australia as part of the third clinical trial of NTCELL.

The choroid plexus (porcine brain) tissue was provided by New Zealand biotech NZeno from its designated pathogen-free facility in Invercargill. Following receipt of an import permit from the Australian Government's Department of Agriculture, Fisheries and Forestry, the tissue was shipped to Australia and transported to research partner, University of Technology Sydney (UTS) in preparation for the manufacturing of NTCELL.

LCT's Research Agreement with UTS and the Australian Foundation for Diabetes Research (refer ASX release 30 March 2022) enables the production of NTCELL in Australia, which would be a new milestone for this project.

Once production of NTCELL has been optimised, it will be manufactured at a Good Manufacturing Practice (GMP) facility for use in the Company's third clinical trial of NTCELL in Parkinson's disease.

LCT Executive Chairman, Professor Bernie Tuch said: "We are delighted to have received the shipment of choroid plexus tissue in Sydney in preparation for the manufacturing of NTCELL in Australia for the very first time.


"This is another key step as we advance our potentially groundbreaking research into Parkinson's disease, with no current treatment available to prevent progression of the disease."

Under an agreement with OptiCellAI, artificial intelligence (AI) technology will be used to optimise and select NTCELL for implantation into the brains of people with early to mid-stage Parkinson's disease, as a potential treatment for the disease.

Regulatory approval from Australia's Therapeutic Goods Administration is required prior to the first clinical trial, with similar trials having previously been undertaken in New Zealand.

The first trial participants are expected to receive treatment in 2024.

More than 10 million people worldwide are living with Parkinson's disease, including around 100,000 Australians, with the disease costing the Australian community an estimated \$10 billion per year. Globally, the Parkinson's disease market is projected to reach US\$11.5 billion by 2029, up from US\$5.7 billion in 2022.



**UTS researcher Iris Cheng with a choroid plexus tissue sample, UTS, Sydney**

Authorised for release by the Board of Living Cell Technologies Limited.

**– Ends –**

**For further information:** [www.lctglobal.com](http://www.lctglobal.com)

**At the Company:**

Bernie Tuch  
Chief Executive  
Mobile: +61 411 461 604  
[bernietuch@lctglobal.com](mailto:bernietuch@lctglobal.com)

**For media queries:**

Anthony Fensom  
Republic PR  
Mobile: +61 407 112 623  
[anthony@republicpr.com.au](mailto:anthony@republicpr.com.au)

## **About NTCELL**

NTCELL is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells that are sourced from a unique herd of designated pathogen-free pigs bred from stock originally discovered in the remote sub-Antarctic Auckland Islands. Choroid plexus cells are naturally occurring 'support' cells for the brain and secrete cerebrospinal fluid (CSF), which contains a range of factors that support nerve cell functions and protective enzymes that are crucial for nerve growth and healthy functioning. In NTCELL, the porcine choroid plexus cells are coated with alginate to protect them from attack by the immune system. Therefore, no immunosuppressive regimen needs to be administered to recipients.

## **About Living Cell Technologies**

Living Cell Technologies Limited (ASX:LCT) is an Australasian biotechnology company that is focused on discovering and developing novel treatments for debilitating conditions such as diabetes and Parkinson's disease.

LCT is listed on the Australian (ASX:LCT) and US (OTCQB:LVCLY) stock exchanges. The Company is incorporated in Australia, with its operations based in Australia and New Zealand.

For more information, visit [www.lctglobal.com](http://www.lctglobal.com) or follow @lctglobal on Twitter, Facebook or LinkedIn.

## **References to previous ASX releases**

- 24 January – LCT signs Service Agreement with NZeno
- 30 March – LCT signs Research Agreement with UTS
- 23 May – Artificial intelligence to advance NTCELL production
- 29 July – Quarterly Activities Report

## **Forward-looking statements**

This document may contain certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising," "probable", "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.